SIR Foundation Receives Major Gift to Support Research Grants and Panel on Uterine Health

The Society of Interventional Radiology (SIR) Foundation announced a major gift from John Lipman, MD, FSIR, of Atlanta, that will propel uterine fibroid research forward. This gift will support four years of funding for SIR Foundation’s newly announced Dr. Scott C. Goodwin Uterine Artery Embolization Grant and five years of funding for the Dr. James B. Spies Global Summit on Uterine Fibroid and Adenomyosis Research. The announcement was made at the SIR Foundation Gala on March 5 during the SIR 2023 Annual Scientific Meeting.

The Dr. Scott C. Goodwin Uterine Artery Embolization Grant is focused on advancing uterine fibroid and uterine artery embolization research and will launch in October 2023. The first Dr. James B. Spies Global Summit on Uterine Fibroid and Adenomyosis Research will be hosted in June 2023.

“Research into uterine fibroids and adenomyosis and the minimally invasive treatments that can address these conditions, such as uterine artery embolization, are invaluable in providing care to women,” said SIR Foundation Board Chair Theresa M. Caridi, MD, FSIR. “We are incredibly grateful to Dr. Lipman for his personal commitment to advancing the future of interventional radiology for patients and our colleagues in all practice settings.”

Scott C. Goodwin, MD, FSIR, and James B. Spies, MD, FSIR, are highly regarded pioneers of uterine fibroid research, having led the SIR Foundation’s Fibroid Registry, the largest collection of data on uterine fibroids, and conducted foundational research into uterine artery embolization. Dr. Goodwin and Dr. Spies are long-term members of the SIR, having each served as SIR president, as well as members of SIR Foundation’s leadership.

Dr. Lipman is a widely recognized expert on uterine fibroids and uterine fibroid embolization (UFE), having performed more than 10,000 UFE treatments throughout his career. Since 2015, he has served as founder and medical director of the Atlanta Fibroid Center, a renowned outpatient medical center treating patients from around Atlanta, the United States and world. In addition to his medical practice, Dr. Lipman is an active public speaker and advocate, delivering regular lectures and making media appearances to ensure more widespread knowledge about uterine fibroids among both medical and general audiences.

“Dr. Goodwin and Dr. Spies have had a lasting and transformative impact on research into uterine fibroids and the safe and effective procedure of uterine artery embolization,” said Dr. Lipman. “I am inspired by their decades-long service as physicians, researchers, educators and advocates, and grateful to have this opportunity to support ongoing research into this historically underfunded area of care afflicting historically underserved women in particular.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version